title: Pathophysiological role of extracellular purinergic mediators in the control of intestinal inflammation.
abstract: Purinergic mediators such as adenosine 5'-triphosphate (ATP) are released into the extracellular compartment from damaged tissues and activated immune cells. They are then recognized by multiple purinergic P2X and P2Y receptors. Release and recognition of extracellular ATP are associated with both the development and the resolution of inflammation and infection. Accumulating evidence has recently suggested the potential of purinergic receptors as novel targets for drugs for treating intestinal disorders, including intestinal inflammation and irritable bowel syndrome. In this review, we highlight recent findings regarding the pathophysiological role of purinergic mediators in the development of intestinal inflammation.
authors.affiliation: Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Osaka 567-0085, Japan ; Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan ; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo 102-0075, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kurashima
authors.affiliation: Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan ; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo 102-0075, Japan ; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kiyono
authors.affiliation: Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Osaka 567-0085, Japan ; Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan ; International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan ; Department of Microbiology and Immunology, Kobe University School of Medicine, Kobe 650-0017, Japan ; Graduate School of Pharmaceutical Sciences and Graduate School of Dentistry, Osaka University, Osaka 565-0871, Japan.
authors.forename: Jun
authors.identifier: 0000-0002-6237-3289
authors.initials: J
authors.lastname: Kunisawa
mesh_terms: D000244:Adenosine Diphosphate / Q000737:chemistry; D000255:Adenosine Triphosphate / Q000737:chemistry; D000818:Animals; D017209:Apoptosis; D003141:Communicable Diseases / Q000473:pathology; D006706:Homeostasis; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D007413:Intestinal Mucosa / Q000473:pathology; D007422:Intestines / Q000473:pathology*; D043183:Irritable Bowel Syndrome / Q000473:pathology; D009336:Necrosis; D058469:Receptors, Purinergic P2X / Q000378:metabolism*; D058470:Receptors, Purinergic P2Y / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D058469:Receptors, Purinergic P2X; D058470:Receptors, Purinergic P2Y; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate